Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2018-04-13 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
广发证券股份有限公司关于公司发行股份及支付现金购买资产暨关联交易一次反馈意见的回复之核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed reply to feedback from the China Securities Regulatory Commission regarding a transaction involving the issuance of shares and cash payment for asset acquisition and related party transactions by Quantum Hi-Tech (China) Biological Co., Ltd. It includes extensive financial data, explanations of the transaction rationale, funding sources, and legal and financial due diligence opinions. The content is consistent with a formal regulatory response related to a capital/financing transaction involving issuance of shares and cash payment for asset acquisition. The document is lengthy (15,000 characters) and contains substantive financial and transaction details, not merely an announcement or certification. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2018-04-13 Chinese
关于《中国证监会行政许可项目审查一次反馈意见通知书》之反馈意见补充和修订公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding feedback and supplementary revisions related to an administrative licensing project review by the China Securities Regulatory Commission (CSRC). It references prior submissions and ongoing regulatory approval processes for a share issuance and asset purchase transaction. The document is short (852 characters) and primarily serves as an update on regulatory feedback and the company's response, rather than containing detailed financial data or full report content. It does not present financial statements, audit results, or detailed management discussion. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and compliance updates that do not fit other specific categories.
2018-04-13 Chinese
关于《中国证监会行政许可项目审查一次反馈意见通知书》的回复（修订稿）
Regulatory Filings Classification · 95% confidence The document is a detailed response to the China Securities Regulatory Commission (CSRC) regarding an administrative licensing project review feedback notice. It contains extensive financial data, explanations about share transfers, funding sources, business operations, and strategic considerations related to a significant transaction involving the acquisition of shares in Shanghai Ruizhihua Chemical Research Co., Ltd. (睿智化学). The document includes financial tables, detailed disclosures, and independent financial advisor and legal opinions. It is clearly a comprehensive regulatory filing related to a major transaction and compliance with regulatory requirements, rather than a typical annual report, earnings release, or other standard financial report. The document is lengthy (15,000 characters) and contains substantive financial and operational information, but it is framed as a reply to regulatory feedback rather than a standalone financial report. Given the nature of the content and the regulatory context, this document best fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents that do not neatly fit into other categories.
2018-04-13 Chinese
上海东洲资产评估有限公司关于《量子高科（中国）生物股份有限公司发行股份购买资产行政许可项目审查一次反馈意见通知书》之反馈意见回复
Audit Report / Information Classification · 95% confidence The document is a detailed response from an asset appraisal company to the China Securities Regulatory Commission regarding the administrative licensing project for the issuance of shares to purchase assets by Quantum Hi-Tech (China) Biological Co., Ltd. It discusses in depth the accounting treatment of identifiable net assets and goodwill in a non-controlling business combination, referencing specific Chinese Accounting Standards (Enterprise Accounting Standards No. 20) and detailed valuation methodologies including income approach and discount rates. It also includes extensive financial data, forecasts, and industry analysis related to the acquired company's performance and market position. The content is technical, focused on audit and valuation opinions, compliance with accounting standards, and risk disclosures related to goodwill impairment. This is consistent with an Audit Report / Information filing, which includes standalone audit or valuation reports and related accounting principles and assessments, but is not a full Annual Report or Interim Report. The document length (15,000 characters) and detailed financial and accounting content confirm it is a substantive report, not a brief announcement or certification. Therefore, the appropriate classification is AR (Audit Report / Information).
2018-04-13 Chinese
广东正中珠江会计师事务所（特殊普通合伙）关于《中国证监会行政许可项目审查一次反馈意见通知书》（180154号）反馈意见的回复
Audit Report / Information Classification · 95% confidence The document is a detailed response from an accounting firm to the China Securities Regulatory Commission regarding feedback on an administrative licensing project review. It extensively discusses accounting standards compliance, financial evaluations, asset valuations, goodwill recognition, and financial risk disclosures related to a corporate transaction involving a significant acquisition. The content includes detailed financial data, accounting principles, and risk assessments, indicating it is a comprehensive audit or review report rather than a simple announcement or summary. The presence of detailed financial analysis and accounting standard references aligns with the characteristics of an Audit Report / Information filing, which includes standalone audit reports and applied accounting principles. It is not an Annual Report (10-K) as it does not cover full company activity and yearly financial performance comprehensively, nor is it a Regulatory Filing (RNS) or Report Publication Announcement (RPA) since it contains substantive financial data and analysis. Therefore, the document best fits the Audit Report / Information (AR) category.
2018-04-02 Chinese
广东正中珠江会计师事务所（特殊普通合伙）关于公司发行股份及支付现金购买资产重组事项变更签字注册会计师的说明
Audit Report / Information Classification · 95% confidence The document is a formal statement from an accounting firm regarding a change in the signing auditors for a specific asset restructuring involving Quantum Hi-Tech (China) Biological Co., Ltd. It references previously issued audit review reports for various periods in 2016 and 2017 and confirms their compliance with laws and regulations. The document does not contain the audit reports themselves but rather an explanation about the change in signatories and a confirmation of the validity of prior reports. The length is short (974 characters), and the content is primarily an explanatory note about audit signatory changes, not the audit report itself. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or other financial report type.
2018-04-02 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.